citalopram has been researched along with Heart Disease, Ischemic in 12 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Excerpt | Relevance | Reference |
---|---|---|
"The REMIT (Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment) study, a randomized, double-blind, placebo-controlled trial of patients with clinically stable coronary heart disease and laboratory-diagnosed MSIMI." | 9.17 | Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. ( Becker, RC; Boyle, SH; Jiang, W; Kuchibhatla, M; Kuhn, C; O'Connor, C; Ortel, TL; Rogers, JG; Samad, Z; Velazquez, EJ; Williams, RB, 2013) |
"Patients with stable IHD enrolled in the REMIT (Responses of Mental Stress-Induced Myocardial Ischemia to Escitalopram) study underwent psychometric assessments, transthoracic echocardiography, and platelet aggregation studies at baseline and after 3 mental stress tasks." | 5.19 | Sex differences in platelet reactivity and cardiovascular and psychological response to mental stress in patients with stable ischemic heart disease: insights from the REMIT study. ( Becker, RC; Boyle, S; Ersboll, M; Jiang, W; Kuhn, C; O'Connor, CM; Ortel, TL; Rogers, JG; Samad, Z; Velazquez, EJ; Vora, AN; Williams, R; Zhang, Y, 2014) |
"The REMIT (Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment) study, a randomized, double-blind, placebo-controlled trial of patients with clinically stable coronary heart disease and laboratory-diagnosed MSIMI." | 5.17 | Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. ( Becker, RC; Boyle, SH; Jiang, W; Kuchibhatla, M; Kuhn, C; O'Connor, C; Ortel, TL; Rogers, JG; Samad, Z; Velazquez, EJ; Williams, RB, 2013) |
"Conclusion In patients with stable ischemic heart disease, mental, but not exercise, stress-induced left ventricular ejection fraction change significantly predicts risk of future adverse cardiovascular events." | 2.84 | Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. ( Babyak, MA; Becker, RC; Boyle, SH; Jiang, W; Kuhn, C; O'Connor, CM; Ortel, TL; Rogers, JG; Samad, Z; Sun, JL; Velazquez, EJ; Williams, RB; Wilson, JL, 2017) |
"Sertraline is a reasonable first-line choice in patients with IHD and depression, whereas the role of citalopram as the first-line agent should be reconsidered." | 2.61 | Efficacy and acceptability of antidepressants in patients with ischemic heart disease: systematic review and meta-analysis. ( Barbui, C; Caruso, R; Gastaldon, C; Grassi, L; Hotopf, M; Ostuzzi, G; Papola, D; Rayner, L; Turrini, G, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (8.33) | 29.6817 |
2010's | 11 (91.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ostuzzi, G | 1 |
Turrini, G | 1 |
Gastaldon, C | 1 |
Papola, D | 1 |
Rayner, L | 1 |
Caruso, R | 1 |
Grassi, L | 1 |
Hotopf, M | 1 |
Barbui, C | 1 |
Jiang, W | 5 |
Velazquez, EJ | 5 |
Kuchibhatla, M | 1 |
Samad, Z | 4 |
Boyle, SH | 3 |
Kuhn, C | 4 |
Becker, RC | 4 |
Ortel, TL | 4 |
Williams, RB | 3 |
Rogers, JG | 3 |
O'Connor, C | 1 |
Lim, GB | 1 |
Burg, MM | 1 |
Soufer, R | 1 |
Shiyovich, A | 1 |
O'Connor, CM | 4 |
Al Mheid, I | 1 |
Quyyumi, AA | 1 |
Boyle, S | 1 |
Ersboll, M | 1 |
Vora, AN | 1 |
Zhang, Y | 1 |
Williams, R | 1 |
Harrison, RW | 1 |
Wilson, J | 1 |
Tolentino, JC | 1 |
Schmidt, JJ | 1 |
Schmidt, GJ | 1 |
Mesquita, CT | 1 |
Schmidt, SL | 1 |
Sun, JL | 1 |
Babyak, MA | 1 |
Wilson, JL | 1 |
Pogosova, GV | 1 |
Koltunov, IE | 1 |
Karpova, AV | 1 |
Eliseeva, NA | 1 |
Sapunova, ID | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT Trial)[NCT00574847] | Phase 4 | 127 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
Effect of Acupressure on Pain, Anxiety and Vital Signs in Patients With Coronary Angiography: A Randomized Controlled Study[NCT05082506] | 105 participants (Anticipated) | Interventional | 2021-12-15 | Not yet recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: week 6
Intervention | fmol/mg (Mean) |
---|---|
Escitalopram | 139.7 |
Placebo | 160.4 |
The Beck Depression Inventory II (BDI-II) is a 21 question, self-administered measure of depressive symptoms. Score range, 0 to 63 (higher score=greater severity of depressive symptoms). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week
Intervention | units on a scale (Mean) |
---|---|
Escitalopram | 7.4 |
Placebo | 7.0 |
hostile affect, 0 to 5 (higher score=greater levels of hostile affect). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
Intervention | units on a scale (Mean) |
---|---|
Escitalopram | 1.6 |
Placebo | 1.8 |
Score ranges: hostility, 0 to 27 (higher score=greater levels of hostility)/ End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
Intervention | units on a scale (Mean) |
---|---|
Escitalopram | 9.9 |
Placebo | 10.3 |
End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 week
Intervention | percentage of change (Number) |
---|---|
Escitalopram | 45.8 |
Placebo | 52.5 |
"A standard 12-lead Electrocardiograph (ECG) will be recorded at 1-minute intervals during the last 3 minutes of each rest period, the 3 minutes of the mental stress testing, and during exercise testing. Heart rate will be determined from the ECGs.~Mental Stress Induced Change in heart rate will be calculated by taking the mean of the mental stress heart rate measurements minus the resting heart rate measurements. End point values adjusted for baseline values age and sex." (NCT00574847)
Timeframe: baseline, 6 weeks
Intervention | beats/minute (Mean) |
---|---|
Escitalopram | 6.34 |
Placebo | 9.1 |
Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Diastolic Blood Pressure will be calculated by taking the mean of the mental stress Diastolic blood pressure measurements minus the resting Diastolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6
Intervention | mm Hg (Mean) |
---|---|
Escitalopram | 11.4 |
Placebo | 12.2 |
Blood pressure will be measured the last 3 minutes of the 20 minute calibration period (resting), every minute during the 3 minutes mental stress testing, the last 3 minutes of the 6 minute rest periods between mental stress testing, and every minute during and after the physical stress testing with an automatic oscillometric blood pressure monitor (Quinton Electronics). Mental Stress Induced Change of Systolic Blood Pressure will be calculated by taking the mean of the mental stress systolic blood pressure measurements minus the resting Systolic blood pressure. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: Baseline, week 6
Intervention | mm Hg (Mean) |
---|---|
Escitalopram | 19.3 |
Placebo | 23.6 |
Score range, 10 to 50 (higher score = greater levels of perceived stress). End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
Intervention | units on a scale (Mean) |
---|---|
Escitalopram | 21.4 |
Placebo | 21.8 |
(NCT00574847)
Timeframe: Baseline to week 6
Intervention | percentage of participants (Number) |
---|---|
Escitalopram | 71.9 |
Placebo | 44.4 |
MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: Week 6
Intervention | percentage of participants (Number) |
---|---|
Escitalopram | 34.2 |
Placebo | 17.5 |
MSIMI is defined by the following: compared to rest, 1) any development of new abnormal wall motion; 2) reduction of LVEF 8% and/or; 3) deviation (depression or elevation) of ST-segment of ECG in 2 or more leads lasting for 3 consecutive beats, occurring during at least one of the 3 mental stress tasks. (NCT00574847)
Timeframe: week 6
Intervention | percentage of participants (Number) |
---|---|
Escitalopram | 66.1 |
Placebo | 83.9 |
End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
Intervention | nM (Mean) |
---|---|
Escitalopram | 4202.4 |
Placebo | 210.1 |
STAI measures anxiety. The questionnaire asks the patients how they feel and allows them to respond on a frequency scale that ranges from 1(not at all) to 4(almost always/very much so). Scores range from 20-80 and the higher the score the greater the anxiety level. This applies to both the Trait and State scales. End point values adjusted for baseline values age and sex. (NCT00574847)
Timeframe: 6 weeks
Intervention | units on a scale (Mean) | |
---|---|---|
Trait | State | |
Escitalopram | 31.2 | 27.9 |
Placebo | 32.0 | 29.5 |
1 review available for citalopram and Heart Disease, Ischemic
Article | Year |
---|---|
Efficacy and acceptability of antidepressants in patients with ischemic heart disease: systematic review and meta-analysis.
Topics: Adult; Antidepressive Agents; Citalopram; Depression; Humans; Myocardial Ischemia; Quality of Life; | 2019 |
5 trials available for citalopram and Heart Disease, Ischemic
Article | Year |
---|---|
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial.
Topics: Aged; Citalopram; Coronary Disease; Disease Progression; Double-Blind Method; Electrocardiography; E | 2013 |
Sex differences in platelet reactivity and cardiovascular and psychological response to mental stress in patients with stable ischemic heart disease: insights from the REMIT study.
Topics: Aged; Antidepressive Agents, Second-Generation; Blood Platelets; Citalopram; Double-Blind Method; Fe | 2014 |
Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study.
Topics: Citalopram; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Platelet Ag | 2015 |
Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients.
Topics: Aged; Citalopram; Disease-Free Survival; Female; Humans; Male; Mental Health; Middle Aged; Multivari | 2017 |
[Clinical efficacy of escitalopram in patients with ischemic heart disease and comorbid depression].
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depression; Female; Humans; Male; | 2009 |
6 other studies available for citalopram and Heart Disease, Ischemic
Article | Year |
---|---|
Coronary artery disease: Antidepressant treatment for mental stress-induced myocardial ischaemia.
Topics: Citalopram; Coronary Disease; Female; Humans; Male; Myocardial Ischemia; Selective Serotonin Reuptak | 2013 |
Therapy for mental stress-induced myocardial ischemia.
Topics: Citalopram; Coronary Disease; Female; Humans; Male; Myocardial Ischemia; Selective Serotonin Reuptak | 2013 |
Therapy for mental stress-induced myocardial ischemia.
Topics: Citalopram; Coronary Disease; Female; Humans; Male; Myocardial Ischemia; Selective Serotonin Reuptak | 2013 |
Therapy for mental stress-induced myocardial ischemia--reply.
Topics: Citalopram; Coronary Disease; Female; Humans; Male; Myocardial Ischemia; Selective Serotonin Reuptak | 2013 |
Sex differences in mental stress-induced myocardial ischemia: are women from venus?
Topics: Blood Platelets; Citalopram; Female; Humans; Male; Myocardial Ischemia; Platelet Activation; Sex Cha | 2014 |
Mental Stress-Induced Myocardial Ischemia Related to Generalized Anxiety Disorder in a Patient With Acute Coronary Syndrome and Normal Coronary Arteries.
Topics: Acute Coronary Syndrome; Anxiety Disorders; Citalopram; Computed Tomography Angiography; Coronary An | 2016 |